These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent. Anderson JL J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369 [TBL] [Abstract][Full Text] [Related]
6. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). Johnson ES; Cregeen RJ Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction. Seabra-Gomes R; Aniceto Silva J; Aleixo A; Real T; Freire I; Torres I; Freitas R; Crespo F Drugs; 1987; 33 Suppl 3():169-74. PubMed ID: 3315586 [TBL] [Abstract][Full Text] [Related]
8. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. Monassier JP; Hanssen M Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540 [TBL] [Abstract][Full Text] [Related]
9. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Monk JP; Heel RC Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411 [TBL] [Abstract][Full Text] [Related]